0000950005-12-000002.txt : 20120110 0000950005-12-000002.hdr.sgml : 20120110 20120110164218 ACCESSION NUMBER: 0000950005-12-000002 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20120110 DATE AS OF CHANGE: 20120110 GROUP MEMBERS: ALTA BIOPHARMA MANAGEMENT III, LLC GROUP MEMBERS: ALTA BIOPHARMA PARTNERS III GMBH & CO. BETEILIGUNGS KG GROUP MEMBERS: ALTA BIOPHARMA PARTNERS III, L.P. GROUP MEMBERS: ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC GROUP MEMBERS: EDWARD HURWITZ GROUP MEMBERS: EDWARD PENHOET GROUP MEMBERS: FARAH CHAMPSI SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: THRESHOLD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001183765 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943409596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81377 FILM NUMBER: 12520383 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 474 8200 MAIL ADDRESS: STREET 1: 170 HARBOR WAY STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALTA BIOPHARMA PARTNERS III LP CENTRAL INDEX KEY: 0001257444 IRS NUMBER: 050573803 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE EMBARCADERO CENTER, SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 4153624022 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER, SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 SC 13G/A 1 f12e10002_13g.htm SCHEDULE 13G/ AMENDMENT 2 UNITED STATES


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549



SCHEDULE 13G

(Amendment No. 2 )*


UNDER THE SECURITIES EXCHANGE ACT OF 1934



THRESHOLD PHARMACEUTICALS INC.

(Name of Issuer)


Common Stock

(Title of Class of Securities)


885807107

(CUSIP Number)



December 31, 2011

(Date of Event That Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)



*This Amendment No. 2 to Schedule 13G is being filed in order to update our 1st amendment, filed with the Securities and Exchange Commission on February 1, 2010.


The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Page 1 of 14 Pages



 


CUSIP No. 885807107

Page 2 of 14 Pages

  





(1) Names of Reporting Persons.


Alta BioPharma Partners III, L.P.

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


Delaware


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                    3,161,128 (a)

(6)

Shared Voting Power                                       -0-

(7)

Sole Dispositive Power                            3,161,128 (a)

(8)

Shared Dispositive Power                                -0-

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


3,161,128 (a)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


6.3%

(b)

(12)

Type Of Reporting Person


PN


(a)

Alta BioPharma Partners III, L.P. (“ABPIII”) has sole voting and dispositive control over 2,312,221 shares of common stock (“Common Stock”)  and warrants to purchase 848,907 shares of Common Stock of Threshold Pharmaceuticals, Inc. (the “Issuer”), except that Alta BioPharma Management III, LLC (“ABMIII”), the general partner of ABPIII, and Farah Champsi (“Champsi”), Edward Hurwitz (“Hurwitz”) and Edward Penhoet (“Penhoet”), directors of ABMIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about ABPIII is set forth in Attachment A hereto.

(b)

The percentage set forth in row (11) is based on an aggregate of 49,128,475 shares of Common Stock outstanding as of October 31, 2011 as reported in the Issuer’s 10-Q filing for the quarter ended September 30, 2011.



 


CUSIP No. 885807107

Page 3 of 14 Pages

  





(1) Names of Reporting Persons.


Alta BioPharma Partners III GmbH & Co. Beteiligungs KG

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


Germany


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                    212,298 (c)

(6)

Shared Voting Power                                       -0-

(7)

Sole Dispositive Power                            212,298 (c)

(8)

Shared Dispositive Power                                -0-

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


212,298 (c)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


0.4%

(b)

(12)

Type Of Reporting Person


PN


(c)

Alta BioPharma Partners III GmbH & Co. Beteiligungs KG (“ABPIIIKG”) has sole voting and dispositive control over 155,287 shares of Common Stock and warrants to purchase 57,011 shares of Common Stock, except that ABMIII, the managing limited partner of ABPIIIKG, and Champsi, Penhoet, and Hurwitz directors of ABMIII, may be deemed to share the right to direct the voting and dispositive control over such stock.  Additional information about ABPIII is set forth in Attachment A hereto.




 


CUSIP No. 885807107

Page 4 of 14 Pages

  





(1) Names of Reporting Persons.


Alta BioPharma Management III, LLC

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


Delaware


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                                     -0-

(6)

Shared Voting Power                                       3,373,426 (d)

(7)

Sole Dispositive Power                                            -0-

(8)

Shared Dispositive Power                                3,373,426 (d)

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


3,373,426 (d)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


6.7%

(b)

(12)

Type Of Reporting Person


OO


(d)

ABMIII shares voting and dispositive power over the 2,312,221 shares of Common Stock and warrants to purchase 848,907 shares of Common Stock beneficially owned by ABPIII and the 155,287 shares of Common Stock and warrants to purchase 57,011 shares of Common Stock beneficially owned by ABPIIIKG. Additional information about ABPIII is set forth in Attachment A hereto.




 


CUSIP No. 885807107

Page 5 of 14 Pages

  





(1) Names of Reporting Persons.


Alta Embarcadero BioPharma Partners III, LLC

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


California


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                    77,902(e)

(6)

Shared Voting Power                                       -0-

(7)

Sole Dispositive Power                            77,902(e)

(8)

Shared Dispositive Power                                -0-

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


77,902(e)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


0.2%

(b)

(12)

Type Of Reporting Person


OO


(e)

Alta Embarcadero BioPharma Partners III, LLC (“AEBPIII”) has sole voting and dispositive control over 56,982 shares of Common Stock and warrants to purchase 20,920 shares of Common Stock, except that Champsi, Penhoet, and Hurwitz, managers of AEBPIII, may be deemed to share the right to direct the voting and dispositive control over such stock.  Additional information about ABPIII is set forth in Attachment A hereto.




 


CUSIP No. 885807107

Page 6 of 14 Pages

  





(1) Names of Reporting Persons.


Farah Champsi

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


United States


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                                     -0-

(6)

Shared Voting Power                                       3,451,328 (f)

(7)

Sole Dispositive Power                                              -0-

(8)

Shared Dispositive Power                                3,451,328 (f)

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


3,451,328 (f)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


6.9%

 (b)

(12)

Type Of Reporting Person


IN


(f)

Champsi shares voting and dispositive control over the 2,312,221 shares of Common Stock and warrants to purchase 848,907 shares of Common Stock beneficially owned by ABPIII, the 155,287 shares of Common Stock and warrant to purchase 57,011 shares of Common Stock beneficially owned by ABPIIIKG, and the 56,982 shares of Common Stock and warrant to purchase 20,920 shares of Common Stock beneficially owned by AEBPIII. Additional information about ABPIII is set forth in Attachment A hereto.




 


CUSIP No. 885807107

Page 7 of 14 Pages

  





(1) Names of Reporting Persons.


Edward Penhoet

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


United States


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                                   -0-

(6)

Shared Voting Power                                       3,451,328 (g)

(7)

Sole Dispositive Power                                           -0-

(8)

Shared Dispositive Power                                3,451,328 (g)

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


3,451,328 (g)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


6.9%

 (b)

(12)

Type Of Reporting Person


IN


(g)

Penhoet shares voting and dispositive control over the 2,312,221 shares of Common Stock and warrants to purchase 848,907 shares of Common Stock beneficially owned by ABPIII, the 155,287 shares of Common Stock and warrant to purchase 57,011 shares of Common Stock beneficially owned by ABPIIIKG, and the 56,982 shares of Common Stock and warrant to purchase 20,920 shares of Common Stock beneficially owned by AEBPIII.  Additional information about ABPIII is set forth in Attachment A hereto.




 


CUSIP No. 885807107

Page 8 of 14 Pages

  





(1) Names of Reporting Persons.


Edward Hurwitz

(2) Check The Appropriate Box If A Member Of A Group

(a)

(b)

X

(3)

SEC Use Only


(4)

Citizenship or Place of Organization


United States


Number Of

Shares

Beneficially

Owned By

Each

Reporting

Person With


(5)

Sole Voting Power                                                     -0-

(6)

Shared Voting Power                                       3,451,328 (h)

(7)

Sole Dispositive Power                                              -0-

(8)

Shared Dispositive Power                                3,451,328 (h)

(9)

Aggregate Amount Beneficially Owned By Each Reporting Person


3,451,328 (h)

(10)

Check If The Aggregate Amount In Row (9) Excludes Certain Shares


(11)

Percent Of Class Represented By Amount In Row (9)


6.9%

 (b)

(12)

Type Of Reporting Person


IN


(h)

Hurwitz shares voting and dispositive control over the 2,312,221 shares of Common Stock and warrants to purchase 848,907 shares of Common Stock beneficially owned by ABPIII, the 155,287 shares of Common Stock and warrant to purchase 57,011 shares of Common Stock beneficially owned by ABPIIIKG, and the 56,982 shares of Common Stock and warrant to purchase 20,920 shares of Common Stock beneficially owned by AEBPIII.  Additional information about ABPIII is set forth in Attachment A hereto.




 


CUSIP No. 885807107

Page 9 of 14 Pages

  





Item 1.

(a)

Name of Issuer: Threshold Pharmaceuticals, Inc. (“Issuer”)

(b)

Address of Issuer’s Principal Executive Offices:


1300 Seaport Boulevard, Suite 500

Redwood City, CA 94063

Item 2.

(a)

Name of Person Filing:


Alta BioPharma Partners III, L.P. (“ABPIII”)

Alta BioPharma Management III, LLC (“ABMIII”)

Alta BioPharma Partners III GmbH & Co. Beteiligungs KG (“ABPIIIKG”)

Alta Embarcadero BioPharma Partners III, LLC (“AEBPIII”)

Farah Champsi (“FC”)

Edward Penhoet (“EP”)

Edward Hurwitz (“EH”)

(b)

Address of Principal Business Office:


One Embarcadero Center, Suite 3700

San Francisco, CA  94111

 (c)

Citizenship/Place of Organization:


Entities:

ABPIII

Delaware

ABMIII

Delaware

ABPIIIKG

Germany

AEBPIII

California



Individuals:

FC

United States

EP

United States

EH

United States



(d)

Title of Class of Securities:

Common Stock

(e)

CUSIP Number:  

885807107


Item 3.

Not applicable.



 


CUSIP No. 885807107

Page 10 of 14 Pages

  





Item 4

Ownership.


Please see Attachment A


 

 

ABPIII

ABMIII

ABPIIIKG

AEBPIII

(a)

Beneficial Ownership

3,161,128

3,373,426

212,298

77,902

(b)

Percentage of Class

6.3%

6.7%

0.4%

0.2%

(c)

Sole Voting Power

3,161,128

-0-

212,298

77,902

 

Shared Voting Power

-0-

3,373,426

-0-

-0-

 

Sole Dispositive Power

3,161,128

-0-

212,298

77,902

 

Shared Dispositive Power

-0-

3,373,426

-0-

-0-

 

 

 

 

 

 

 

 

FC

EP

EH

 

(a)

Beneficial Ownership

3,451,328

3,451,328

3,451,328

 

(b)

Percentage of Class

6.9%

6.9%

6.9%

 

(c)

Sole Voting Power

-0-

-0-

-0-

 

 

Shared Voting Power

3,451,328

3,451,328

3,451,328

 

 

Sole Dispositive Power

-0-

-0-

-0-

 

 

Shared Dispositive Power

3,451,328

3,451,328

3,451,328

 


Item 5.

Ownership of Five Percent or Less of a Class

See Item 4

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.



 


CUSIP No. 885807107

Page 11 of 14 Pages

  





Item 8.

Identification and Classification of Members of the Group

No reporting person is a member of a group as defined in Section 240.13d-1(b)(1)(ii)(J) of the Act.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification


By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


EXHIBITS

A:

Joint Filing Statement



 


CUSIP No. 885807107

Page 12 of 14 Pages

  





SIGNATURE


After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.  


Date:

January 9, 2012


Alta BioPharma Partners III, L.P.

Alta BioPharma Management III, LLC

By: Alta BioPharma Management III, LLC



By:        /s/ Farah Champsi                      

By:       /s/ Farah Champsi              

              Farah Champsi, Director

   

Farah Champsi, Director




Alta Embarcadero BioPharma Partners III, LLC

Alta BioPharma Partners III GmbH &Co.


Beteiligungs KG

By: Alta BioPharma Management III, LLC



By:        /s/ Farah Champsi                      

By:       /s/ Farah Champsi              

          Farah Champsi, Manager

       

Farah Champsi, Director






             /s/ Farah Champsi                      

Farah Champsi




            /s/ Edward Penhoet                      

             /s/ Edward Hurwitz             

Edward Penhoet

Edward Hurwitz




 


CUSIP No. 885807107

Page 13 of 14 Pages

  





Exhibit A

Agreement of Joint Filing

We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of us.

Date:

January 9, 2012

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.  




Alta BioPharma Partners III, L.P.

Alta BioPharma Management III, LLC

By: Alta BioPharma Management III, LLC



By:        /s/ Farah Champsi                      

By:       /s/ Farah Champsi              

              Farah Champsi, Director

   

Farah Champsi, Director




Alta Embarcadero BioPharma Partners III, LLC

Alta BioPharma Partners III GmbH &Co.


Beteiligungs KG

By: Alta BioPharma Management III, LLC



By:        /s/ Farah Champsi                      

By:       /s/ Farah Champsi              

          Farah Champsi, Manager

       

Farah Champsi, Director






             /s/ Farah Champsi                      

Farah Champsi




            /s/ Edward Penhoet                      

             /s/ Edward Hurwitz             

Edward Penhoet

Edward Hurwitz




 


CUSIP No. 885807107

Page 14 of 14 Pages

  






Attachment A



Alta BioPharma Partners III, L.P. beneficially owns 2,312,221 shares of Common Stock and warrants to purchase 848,907 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.


Alta BioPharma Partners III GmbH & Co. Beteiligungs KG beneficially owns 155,287 shares of Common Stock and warrants to purchase 57,011 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.


Alta Embarcadero BioPharma Partners III, LLC beneficially owns 56,982 shares Common Stock and warrants to purchase 20,920 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.


Alta BioPharma Management III, LLC is the general partner of Alta BioPharma Partners III, L.P. and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG and may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds. Alta BioPharma Management Partners III, LLC disclaims beneficial ownership of all such shares, except to the extent of its pecuniary interest therein.


Ms. Farah Champsi is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC.  She may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.  Ms. Champsi disclaims beneficial ownership of all such shares, except to the extent of her pecuniary interest therein.  


Mr. Edward Hurwitz is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC.  He may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds. Mr. Hurwitz disclaims beneficial ownership of all such shares, except to the extent of his pecuniary interest therein.


Mr. Edward Penhoet is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC.  He may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds. Mr. Penhoet disclaims beneficial ownership of all such shares, except to the extent of his pecuniary interest therein.  

 



 


 SC 13G/A 2 12e10002_Threshold-asfiled.pdf PDF VERSION OF 13G/A begin 644 12e10002_Threshold-asfiled.pdf M)5!$1BTQ+C4-)>+CS],-"C8T(#`@;V)J#3P\+TQI;F5AI8V`DAOC/V/,# M(,``G6\(^`T*96YD%LP(#`@-C$R M(#Z@"X@I!X"^,0B)"PKG+ MB8C`"'XA(SSDG(2<.(P+)@4-"! MZ&'$1O0Q2.,YJ\I%K'1*9X,A3=2+GG>[,//GC#S)O%8@3`BG<:\=QA/"OC*' M)KNM.BQ/RVUC-W-[]4(5&FK@]%9NOZELM=:$,\;H0#6FCL,#.LSEJB:N9Y+M M]\N7M.,'(>FX3$"!C.$4,3?6H=QD^>XJR3:J)E/UE]R7&UE<&]M4;A0U%C`8 M_2R>),84ZTKIQ9I.RVHC>9GIT] M'N@QC^/>5F7SL_5@+R[49G,ZKMODT\H8D[WKP8@X"]K\LZS[IZP[P<=8[_3+ M?/E?X,4KP',W^!SQ=OF/82_.L'?X.[%OP#^,&EOS?BOJ["+H%E`#/0+;0H9` M&9!`1IL%V(PY;R,8S-LHYDO&+E)N4@!70WG;[RF'L;V%V&.AJ+.VO3\DY![9 MC@@_8S2DM^,!?.Q)$)E]/Q![@BMK<3VBE:&>`RU^!'&B$U+AP%=XTG7#Z##+ M%>P&,ROLH>V-!M/OO2][W\Z]6CWGLOK@=YI=@O:4TU=7Q#W8U1!F7#R5^%-7 M+54%'E?C)6Q`IG?7%%RS6E>[J]ZR?%37P.1VFZL-[@__.@W- MQL\/]]$FV/EVN%KP@ATL?Q49."DB>/-_@4VGV_TGP`"?"&)*#0IE;F1S=')E M86T-96YD;V)J#38X(#`@;V)J#3P\+T9I;'1EF$C(.\*P$'_QD&'*0\42 MI;DQ+'O&#D^='@_#4+)LTO$O+YW@;GB3#2[9*+O(!J-N]I5VDVZW!(=$$?;+ M+K$4#R),:\GN`AU0K.#T:!_=WN3W0Q&[&)XR0:_]:\OAE<# MUO_\Z=/-:'3S>;A_E!0<6_BS#D](N;9NT5/*D,>:)3@T5N27]2EJ?8JLA;]> MC*YOAE?9Y^%[=LG[G`&.6*7[1PK)X_BT:J83Q:79&"Q:@X4]==2_'ES>?1PP$5T=QB"6P/2TF=Y&&"@3 M;B33<,?`@NGHO%%/]6;%AQ)ME#]]T9][0R7!B_^,`=PY6=3T^1@!=, M1P:6O1:`N^'EX)9EUP.V0P1G,E>(W:$_]\&&(1?]C'WN:JZ"#]U>A`<3::2Z MOV>_[,QH1D`1,VC(@MG,? M@F'^7+#JD=TTS;JH'[IGHA0;X9/C1";N62>A9TJR6*<\:F,BHKUDN@_ZU?-S MM>B".J-5-?FC!=>NQ6$ZH8?(*A"K>"/T/((PU+8/<@F,NW6&(M!;=!\;$L$$%)DR$?0F3#7ZT$"=%DAXJ MY4KM<3,*8Y($^IX8APGQ$>^.\*,U9L\8:[\'+^9)HL]C!^CZ=Z.;+VRX?A[_ MB&?XH$Z"Y'4A,7N"LH];E%#)428AQQUJEGDD@$*[.%X67>A\,'&/YS$@3(*B M9I%]$5T>!>^9M!]"(3;(8FN-G2T6R+_(`RL\L)+0P?>:2P"+A_HQL'+7U.,D M5MPH$1]"JUMH34O+2RA4D*]L)@^^%R3).EAT(SBR8MDL7[%;/_AM7=9%0^]) MP#Z4\W+QM*'S:E8V2$;L0^7H-293KX+_(K+_#41VTV/AI^^6(=$JP:R8D$5I M\`=L*%B^7-;5LBYS-[CJ`L:@8./J3[:JV)3,5T%I1Y\6L-9-]WBBKW,RLG,(S&9%=-UF^X8>"SGCBETH`BF M_[*?SJ&D0JC3&T`2(B5I51)JIEN83$M;E3IK;\D8$4U[5*8$HALC].,V3C8Y MXI0:QAVMWUN%LF77::R;[*\S*FG7F:-UV].F9UD1)9*T^?7,%6?M]E,R2L1NA%T+"V;[)#U#S9%^J@$$8;.SNP!D],8%VY8F73\B), M9;KAA7.9"J;/*#8N*#$0\&+*R@6KZBGD`?NNEU.;9NN:.5U(N>_O[(N"4$:: M17'HXVA59XM%LSKI.?)][WG:)[[U5+^5JYD+1@RS'5!K.RH3- MC&V=8OEBR@9_3F;YXJE@5(NM98I'U!N$K_0+9=.4%>!8L`_%N%[G]5],0"E# M^'%2T%U,(8RA>K-61.B%VGK7)JP0TC=RE-[%-$>`,T:B[V?=Z.'WC=%&3^,GFF1MS4K M@&@OB\F*.$B!;-;CK_1QTG8@#2)K(86PQTIL_6^W:2VTT7]OPV^]7/QES54! MMFR*;VM0#*#HP(\2[YSO*)6AE`?`;FZH]X&[PTRJQ0K1(8?+!;F:KRS&1!NK MK5NG8WW4GOJ"\%*MYU/J#/,YK4Y)<=%K!TA!*`!*`7U94GO>3.;(>]@.?!BJ MQG?Z8FJ3UJYG2SQJZ$4)7QU-B`G\C(C)!'[KG2[G1X25J(7M`I\J`$:(<(>S M+18$0UW8(FR%9>7Y[,S!P5++0UD"0+X`[++>MGVVD,>^]/DLH-<=MB^J%6L# M*)3<,D,*OWOD41\7MF'P["7U-`YX$;AOGKM4*?R'J:V_Q$&'?_YY:&$L>R;V5VQN*C&*'Q]I39UDU4'Q\>'3W0%)1&TB!,4.8@&DV M*%N!=:QMM@IKW90X3^O#Y,2!OAVY0$9C(RJV28#[-'L(_L;8/RBZH&\%\D=M M^R&#^J5LMD+@=<%GE^!&F_25@B"$KRGS,A]#FRC%9$`U`6?[)@H=8^.]])Z1 M;1LAD&E\5#Q#WUR/H9\NQHZ`GAY[IM(XW"E:-BQKMS4229D=?-JM?42J[R75 M'V>HHY']#6(&+@+NK8T).!3+X[XOWESD9M5+@71Y#S>+'4H>D%$JNBOAJB3> MR$4)VIHC+@[/+FWDBQ6V]75BJZ59PJLA'"T/RCMW,N.KT9HAW%2&&UF M]W9O:M+KP)?<=8I/A7LR`?;;'WF0`,AMH?Q//E_R)_=6="G:U">>T5612OI1 MX&W-H1T*%;6`+H*Q\VOSY>:7JV*ISUKZC8]@7W>[QLXD*IM MS^G9L_TNSW?O>^]][WOO^S/S#L2(*(ZZ2:3"N^L+EA:],1Z%Y@)P3V-7I_Y" MP:E31"R52%[=U+YCUZN?KC&(E#HB:?N.ECU-DQTOGR=*@HX=:0X%@N^PUSXB MRAA'_SN:H4A.L7^;R`X[W=:\J_/!ZK+HXVB_120>;&EK#!1_6KR7**4*_2_O M"CS8+MZC+$;_5^&OMP9VA7H_F'^1*,T)_[/MD5#[W:_=OITHX3ZT-Q-3;V5] M)),FO2&]`4WZ-*>@J#M@^*)G0[VND_O7^J^GE%QVG(K4(F9TT__;Y\H76HI` MC&2<,FTKD/<&NYAD3`L MCT'/X^VG%^@]=A$^#]&3L)VG*[P7(O?3('W&%H%ZV"_9A%`'+>/C(\Y.>/?T'=$O.:2/Y)WR]T%CRA;U:4U!;)D4FD\Z9=-R M5.7!&!N1H+TF/01Z&'/Y+3I&`_0,G:(A>H5^RL>DJ_0>?8;9203QNHK9 M*K85Y`-%V#[V*.:C9Q8=8M]CP^P5Y/UM8@*HM:D'U5I;[A:>$<\+KPC\( M[POCPJ^$WX@DVL3M8H/8(9X03XMOBF]*5=*`](STKO2NS&3#G*ED)56Y7^D! M]:HV=:?ZJ/J$^K3ZDGT)S4-=>:BKAK:BJCVHY&$Z2%%SU89`Y^A%T!C]BM&[PO>$Y[$CAX4+PB^$]U#CN'`--<:)R6*:>*OH M$2M!F\5[Q0?%_>*@>$F\*DY@W1S2G5*)M$6Z'[5?EL:EC["2@BS*V?(*>36H M66Z5]\D]\E'LZ`EY0G&8LY*LI"AKE`/*,658>4>YH::IZ>I"T!*U2*U76]0N M];0ZKGZHG;&5VL*VB#V/3E,AO7S3Z7T1N_MGPOU*`$D^K>U2_^B$R_51\4FY6E[!2N8>=%-;A1$?81OHM MNT9?Q\B=PF*Z3(_30=9%&O5K9U@\SMJHL(#UR-\7STH#HD?>Q[Z&%NNWAE\?)E2XL*"Y;DY^4N_MJBVW.R;W,MS-(7W/K5 M6S+G?R5C7GI::DIRDC,Q(=X19[=IJB)+HL`HS^.J].M&CM^0;IG/)E37TMK\_-TCTLW_K'"I8^P M;1N]D`]5N'RZ,6'*&TQ9RC$;\6AD9:&'[LEHKM`-YM<]1F57<]3CKT"\H3A[ MN:L\9,_/HR%[',0X2$:EJWV(598P4Q`J/:N'!-+BD951XZKP&-6N"IZ"(69[ M`D&C;J/74Y&9E>7+SS-8>:.KP2!7F9&8:[I0N3F,H90;JCF,'N;E4(\^E'H>JNZNJ/#QT9++O0=,]WEPG[=W/%.,>C+".F]&HP=T8V"C=[8UB[]]/@3- MSZO=Y,U"UBY/K\[+V.0U*T!0EE&`)+F.EVD5'')YN,;_@&[87&6NYN@#?BS6 M_*A!F_9DG9U?XSX_]6]4X]&CF[VN+&-=ILL7J+AE*)6BF_8,5[OUZKF6_+PA M9Y(UTT,)B3'!$3];",W83,ETYQ*RGIYJQC-R56.+&'JCCDR\+D/(7LE?H944 M;5P)-SP^AAD-8_[\4>=JOA!RMM.E1Z\1-H)KXN.YFD!,HV0[KQ$7^7:9V7*P M3\M&;JZQ>#'?*6HYEA:9E9CM%?EY74:MJ]VI&[68,JKSHI-O=0&F/"N+KW+/ MB)L:T#"Z-WJMMDX-F6?)79#K,P0_MUR:09A#DIP=K?/F!*(]F3G^:*\/2U.)HQB-5KKT MRJ@_&AB9ZFYPZ4Y7=*BV-MKN\4^7-#)UL2?3!YJT23NGW&]1%-OVM\W,YO]?"`1F9`GV3"`.NN70/0*>1OU*-?5/CR7_+H8Q`#DK]T*?%LMCL96+S8U8R%M% M/.T\..I3_P9X`NUEX*U6K=ICZ'\G>!,-VW/IH(2YXY@>"_-9"S(%ZE1C&-&K7U%'0[J+(2-20G:>XJ?42XXVS54K#])F-G+/:\ MQ4Y9[*3%?F"Q9RWVC,6.6:S:8E466V^Q,HNY+59BL;466V4QQ6*2Q42+,??= MX.\"5X%_`7X._`QX"7@1^"$P")P!3@(_`(X!1X&G@5Y@/]`(;#=C_M`*/6BQ MTQ9[SF(G+';<8D#O`&\#8\!KP&5@%'@9 M.`<,`R\``\!A8`\0K%J::DNU%?>-L"YWM=KWC-KWI-IW2.UK4_M:U+XFM2^D M]MVG]FU3^WQJGU>]35NHZ=JMVBW:?"U#2]=2M63-J25H#LVN:9JB29J@88\: M*6*M4%M?QFJ-BXU4VZ`;OZUWC3#[QFV&["IC1G(MU6XNRS!6YAK"0?/F,<*F MAAC[]F.9_-)QGAB;>NQ09HS[?)2>^X=/QIQ6;=V>"[2`%9.*][)A=<&K*M?6 M0]MG:ONXML_49K"S=;2T-M#C_RKE?MG#Y9(FB)Y2CS/ M?DE4,#GAG*!UG^!=5+@L*2LI.RLIJUND&]T"39(\=GUEMS2&,/@%3NJ;L5@I M=,0]3TMQ.&UQB?841T*B/3D^R6E+CH]/3L:I==M2'*DI*0Y[8B)OI3EMJ4ZG M3;/9XQSQ"8G.I.04AZ3^B!W%]['$CKI3&/*<8Y6E'[-5^#B0\1:%3&1Y8\)Y M(VG>*EHW@40A%!4>2%B2F_!-YZO@&::0B&>Z`,;F,:8R=CMCQ?@B^%U$OGY= M$6ZPUO#D$ZPM/'EX\HEFUCIYN)D7V"\-3'Z%FPY/'@YS+5YH8OY0L[([5G/N M!1+9T?.7S4-_$7I];]2XH^#CLS<*9<2Q621,M"R9`ER34Q6(#?$9!5GDP5*8/MBLDB%K#I;2>*N@NK&DIY=)6>+?"/QCC'6:/';0; ML0+H]<>\\_^/_?_00X?$WR'P3M3-:]7AJX/SGMS::6IY_3ID/G-!M':9$7=" MUS;3Y_.M37_6:NAF;GHL&YVVH!4V<^#CUT,*F*T.<\Q6:`MB&;3-JJ`1K=VP M\HS"IC=?9>N$?L`5Q/##XYR?E/R_ZSF6BRSOZ^6F2>_]CI_U\!!@"VE_7I#0IE;F1S=')E86T- M96YD;V)J#3-3^JB]6?BMAO]5D\'"7;1!D=SI)E[595NI0-KZ[T0I0-US-46\60 M\WB]5`RQS"Z/?0LP`&:P;>4-"F5N9'-T%LP(#`@-C$R(#)G$;=;OG-/O`2+2DC2RZ)!W7_1G;_N"]&(`4 M*8F*DW:;GEH@!6`&G45QFC+ZLW%M+F)E\*"R/)9J M\&CB5##.X\QV3?K6[5_/OAT(T2*-$\.R3,0ZW8F),\'L_QMJ1796^Q!9*<*, M7I"<:"-)K)UT1H94(V^W'X.K[4,8F>'M]PUY3JPHC'LL@#G6< M!\R84,4ZT.XCR>B#)_21A9'(4FUB%=R@&8N@P"`5+-T,)3TPP?"9!=4MXS1* MN6_93;&DYS*,\-B$_Y[]PZX.>OGEH:52`)=I'HMCJ[.&BGG"C5WMU#SQWT[P+^+F2OB[NR M816P$,%M"%,'[+ORWCW7[7J[M/CIX*:LFVK;Q.PX4"0OS64LCR$U]EHCJ;.! MDY-RI).Q0]`0WB\O-FW!+M?5S:JHPTC!%^_@*#PHX#AUNX4V840>2MYU[;I< M7Y^S;^(;^Y#"@\DGG<+'(-0<@Q7QG$#SU,2YLC`2LD+VYK:@%N_",+.11PN7LW[,+YRJOR[GU9N_8;^_9K0*B#ZN'>J02^3$&5T4B>\T_G-.^"]UC$ M1*3*!$XV':A"6A(GU'QK`C4MXU1-H:9&D*D17KV`:"3A"%[&P:7`JZD'2\HN M##/E[/KVY17[OG%-:N?*F+9Y6+?I.9O&_9;W^H&8B9"UVQTV%&=4N!O/]ADI'_#J M6^Q#91,"X`X&].6TP-&8S(%X66[+VW68PG_FZV*S>?)BA,G3`S+N*0$9"`E[ M\^CVLRT!KX,%N[2[G0J>X)T=,\1<&WU4O)U*^ZE>%O,5ZS7&>S]$4C[D%X<- MG_@'N1^D^EV?A@#"5.X+X=W.(,G#76K`?EBWJPZ7(Q`J`^\YREDC7Q7H+=)# M)X.+DI-9MQ64%@EC.^X]I#MN3D]SLP"\&CNWZEPE]Q&DL\G..V*;L MX4C&U*&2IJ>6;QEX",S>\V=B@[1_C$V7&Z2G`'J6ACN,]E]\/DP#-0]ALJ2Q MV`/JRS`:-:,D.@$2TCGU?X\AR<[!<\G=?O#PF>D8-8!DPWBY\6ZN:^: M=;O^6`Z#Z/GX/#]N;+'_YX2-RK,I8,PI8)ZCX1\8-F,U#^!Q<7,(T)?&SO&` M\7F10L[X1R2[RFB[IC\MV569MM;WW&/Z\M[7%1?N?&59EZYAZ[2+N^J!'K8M MW16_J$BW$('27`0(1V586V&CLD3[S`X%PKI!$4I9H\V9[ M8O@#VQZS+4=]BKA7RZ6A#Z=%2@]A6FJ[.I-1$56#-/OZS.]@*BD83I>)!T MAG>Z^%N%]F22:KQYR.'T'^S!Q6S5U7T7RV7MVTMT+5RS16*,[-;VM,=#D5+-@. M^/,K_ITM(G^$0WCS9!)P:<:E^K$34"TZ&J36!.#PG$G`GT6#7DPTDC,-.]<[ MV%W-1FO6#G=0T;P$%0&_EKVY95<;\`38L&D\AN4]"KMRV])K,!N]O7RB$0YP M/QBH?U<]>H2ST]26J.-H$1D@$JWBUN(973\8]6DV\&-RX2;^%"$A9&#O7??W MOU-Z'B,Z!])/4Y$4<3[H[9@(U3D$[HAH[)G<3=F=5X[X2G!']L@M0AM#?YG: MRZ4FGCWIQ,_:RZ4ACIYV8K'OQ.)W[>72W@I-GM3/GNY+Z[O3!_/T]I1'RI3R MKF=OME)K^^`W6U<;W[SVY\7]`90]`#E`4C@DCU[F2"6':DQJ`+J7DN\TZ%+$ MC&>']P-WNTL!=NWO`&+$Z:\7ES=XMFS,@]^0_:Z*AC5(_TB?V#_O-;UWE M89-Q+@>*F6Y*3X4L1!N[3;$-W:G28U'7_J$-\47#VHJ>F#MNFUZ1UL/OWEIN19(X_^#>5KL$3:!>1YHA.94#(J>: M!VP$LIEF(YW2T:*TA[U['GU[BI:,L!Z84,QZMW)65X)[$\U66,6JVBR8!KXIML2SO2IN+D,-_<^6<"Z693%.^ M[URB<]%>0<3&*PPEO:RR2U0#=;%A]^ZZ#?L=!!FD^K7%U`72.07%WXJZ<`'$ MXU3*?-\,2>8]>.4(ZFI5W-TW:W)@UR2A+Q==-*'6X-/1!!]=L+\_U(_K]A<[ MAV_V7F_CR<;Q>,6=+CS-W316\Y<+FLPYY4VY755E:Z?T3??^-YN1R<"JN%C7 M3D<-_AH61&XW*N=M!<9QP\A(K\A(=\43>U_Z]XL2,"T05ZR;2G"Y6ZYWP(1G M'AF*(S_6XE*OEZNV>ZZL2A!+B+EWCJV\)5"YR(,C82<@-]G.$`>\INTM0Y_, MHHSR#-8\S%?.XXB$8G:Q6&`8]:^V<)?UMN=2*](O*Y<>O-OAG/!>ND$IWE%,B_9'KBCA'N M6=:E)2;NJE<1^.B.$R7I*D`;E8U+8&YTWO%$R>XILVP1B*PI=YK9JK>F/)&C M::_8L;KWX,X%J[RUDMAHH?=^E6%G]U>MB#-6+)>ANWZB'U.X!UO#P]-43D_G M7-"GL?KSX%QE]*C=(]NG9$8\+,##HP(96ZU`M9"@U#3_'SY)OP*9I!3]W;7W3B.\P\`SFA8N2CLPZ?X&46;O;"3O^`([SX`O_`V/ MX1Z9`L%C,^.`*\X"$`C?'PXOOYO`Z6C;]GM>F-5`;9N M.'8A;;A<0_1:$;V_#^^Q;FL2664*D9&I[K_6\_4Z, M3#>P>7W*YCJEGQM,#/4_$K(IV0%OB/Y6*O&6E4FHR;SX``S]I5(J,3L^[+.,^5 MO_&:[VHQ9`(Y6YZ1)`Y3Y1!JZ#HT5LK]K.Q_`@P`!.=?6PT*96YDM*'$/+DDL206RW8,-%%LP(#`@-C$R(#7!E+U!A9V4^/@UE;F1O8FH--2`P(&]B:@T\/"]& M:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#(V-3(^/G-TY,LQ>T3$O<2*16HN,XK]%]X#T' M`"F2$FEOTJP]L4`(Q#DXWW=^`(21Y>S[JW>,+/>SF-"8I_!#-.,D21E-$[++ M9_?PS7+&2$%F_R:,Q/#+B$RHU"31,35DL;&=FUE$M2;VS]JU&:?2P(-,4BID MY]%0S0EC-,&A<=NZ_^OLEXX0Q36-#4D23I4^B*$))_AO;5L1SHH/$4KAIM=A MY40'05%/TL5\]OU\#HJ0^?V,Q50YN=A0S-`$UB1O"X#_\Y_QNN#O3RRX.6U`!>():+E M",S*)4JT4OH=5DYT$!3U)`%'P&*I:6P'+5@7?)_$8&.#UD/T58L^<^B_#]C[ MD+S.-OF>5``'#^Y#L'9`WN9;][RKBW*)$*K@)M_MJW)/R6FLK#R="BI.@354 MSP@[W#`W''5*\15L**?<^;K.G.2+HKI99;M-!JS9U27H0:ZOK\G5YO9'\IT; M;$NK'J(\`FL75O"!P0,7XCY2F[B9@APJUFG84L/7E^ M.?U>@E[871%/#N\^E`WSODPK\'0VU.H9A;B@NJ\01`)/`)XZ&^_)3V`^'ERU M1ALZAH*@P"<\@TLJ7-AJ6J>YC^MEIL_]N&$^5QA".\SO=#CF'\1$/3FGF`]1 M+P;--42F!@G1(H&DS]Z'88+!R:Y:4)Z8Q(6)5&"8B%HZ!O]P@51`:D@Q.;1C M<(AI&*N;F3FXT^4J7WP@\U5.SK?;7;7=%5F=DXOJ$[F^)^>.KC_GF]M\Y]IO ML/=J%T8JJ!ZV3B5(*1JR2=23Y_S7\>E]<`N+&`EF/,7\,9[Q@!E".LQ\:P0S M`)^-0=:+5/TP=9@_Z@DX`99Q6$D`07NP1,O21#J[OGMU27[=NW1!WI2A#M9/ M\&HRC*"6"0H@01K4Q>:A%3UL0YX+XI*!B;DT(^C:IR0'^^B$$2@40)@%R#4A"*`H` M5X3UWCU8.&FJM!@&R@.$[Z!N@.+&0N+'],>Z)/U[<)&'2)[2?=P7"_M90#ED M@FR]AGPA@B>@DY?*33H,SX-T$+QY+/,[=:.70_52SV&L>X#TS1Q' MIGH$%C,%RT"[;^X:N&\\WU0/]J&LR45>YE"9%%"///F]XZ-+X#!` ML?1PSC?,.+X2L04&%`^A=.=\TIWOP"-QE4$HITL"+49*@M-5LH1=4-)NPMO# M1^9K/,Y@$2)`)[2-GB=.5-"-6Z3C9317TP2!X.+9W[1&""+MZ>P7[8%;]Q+3 M[N6Y@>%5/K/_685XL&JW.0LH357P`0\5YJMFZW.^!/*X]A*&9JY9A[#FP'$) M:'1=.O*\=7-6,/#1[9>(LVED?=".>?5IL7ZX@PK:*Y!;J;LZ*TH"+N_FQVT6 M%MD3Q(%TH/1+B./'M\:(?-2W%1Z+1Q$7!G:K^L\("5R.(_XM8@(X;XL[2]N8 MH-J*?9&7=@]4DS?WY'(-^R((#?N]!S'?P@8G+VO;#6[N3DR?[!L.O00)]-^'HL1N.P!!C@D:HXFYR\]P6C>29F?^9GS$P9>`Q;OC+_]2ODI'J9W MY8>3\@5L&+K#W1X2=JZP=3W$I#X]F9NS.5'LA2[.W$8SIC)$3_K+6'(3JK]5 M.3H">.EU@S`&,_U7,/FEEPV.R0)OLO3H9CQS0]*'D#LJ35U)"BJX:HQI`U!>"(0;]*P[#9>>*8^1VPT5A M>\?1Y/B4F3;%Q\K/9?RVY3O2N0-9/I1+'R!^NG*?X&X1)MD_(((GP?G%#0CY MZ>H_;FX%P.GD4#_P1M'FHB@DJVQ/]EAV?X2-$U>7.`UI(2RIG,%ZI1(A3?;;I>5]9[4L"+MBB(( MC=L0@D_PX)YV"UAZ[HRHDK/8?@=YV7;LW?E293OO0WS9*64[K&;86&"BY,$' M^W#FK-1H-C@4L@R$4*6]F?)/BWQ;6P/)H%YE-3F_^#F,H(@/`,$S4J]RLLG* M;(F%G">*8>D!3+]Y@AE]2B'K8E/4F"KLG%O'.K1GPXHSDC53Q2GOU)6LFZ+,S_;35ZN[+L):"'YD%+PJJ=4E==G%J@?'W986V@H0L`9@Z+^ M[%FD(5!I<]H^L?`W6'?%+E_4U<[RP5XY@WFL83;9$[G-R5V>;W"MGN?"<-4H M!0G$35)7Q`)IC;DKEJO:$D(@(2`B.1GV2RL!/,!^Z\.7#(9N@-2V(_!6!]:$ M))#`\NIC[GO<>_N'Q5]!\+`' MW-EM]5"['11`Z98,`0M=;@#AX;@#8TT!KIW7!":J5S"AH_9Y7<-V80.EA7\F MJWR7UQ5M3B@QNQC(6E2*Y!!!>Q7Z8B**\@1#(SID+XZ^[`[?=L42ZZ7NT3II MO\3^SJR09R$FI60Y<[*A@H"P++7-6#9$V_]$\E\!!@"A)%S^#0IE;F1S=')E M86T-96YD;V)J#38@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I7!E+T]B:E-T;3X^%LP(#`@-C$R(#+>)W5C==B;9!UJF)6TD44O1<=-?O_<" M($5*)*TV[B83"80`W`N<1*01O"X#_\]^P?.#OSRTX.24`"F8(TH@VIK:KRY'+!$M M1V!4)M"BM=*ML':B@Z&H8PDX`BN6FGKMH`3S@M]U`FML=%UE822`/N0RC&2L@A6R1P3%[3*,N&4<_%ANL!$- M,H*-9/#>=]IFUE.$>^+M(R[5M":EC'R=:<%IY'/_7W MT_C5],.YI=C73Q+ZYYM\6Y'KZ^L+\N./5T.DE!"0;(253.`TD`YUJ9]W.&UJ MNKQ+:M8QB>FKQ;I6A6/=P4S4L=/'.L@X"7BN("OXJ3/>+!L2+OLF0&5KY;Y_`N9+7,RW>W* M8E>NLBHGE\5OY/J13!V/W^>;^[QTY1NL?5<";X+B:>=<@G2N()-''7LN=ASX MGX-[F,0`9BS%W#V\VS".FXS%S)<&,`/PZ1!DG2S131&'\:..@1ZPC,-*``C* M@\5Y'8-:N'6]>WM%?MZ[5$UNMJ$*UM_@8S0)<(K#]V0!&XJ^D0`?&,:@$2]& M8MVE]A0@&`M`V#&`[JWF_'N,2P6;;-MVV-@^1E]"^E-B;!^1V,SO%&(D8H%& M0^C7FT][FZ#F:)OP5J*.F6$.4(@Q5N(0J`Z'&T'&&M.N'E28&>0B#XO8DCFH2S"I1RU34M>6@[5EI*,:]=J'7/SO,T?R.6WL-Y7H+D\L2!\+^53V]ML MOB2>'/2H,:.M70O54%F%D`<@"%`?;5&[FII8<%Y0O'>_0'Y*OT$Y^41^655+ MJZS&(D(8*S,',NB!5M"ZAU7`2+5QI*%$@A5.D MB(Z-ZJ@:B!X)6^^)=S:5F3/=XY"Z[&9V4G&V@\)ZUG$0HL<3Q1]W[HIU3OY5 M6%%[6SR##'!_K!@X+0]4G]'$%J,D(HT$/49-2?1S:%DZD'7Q8J99#UM\"3&9 M'"-6RQ@U!MO+_ATP.P+L;`\]9&T/3P\I-G4\>-1..1!RIA=`/0;@62Z^7MRUG=1UV.E6V+U9[7?%?E6M MON;MV'N-T!L--$K;US]_69R)5`V@9,90>M&[UXJRCG\G`+D8.X7HSZ+#+S"D M()H&`\FK*V$OW;Y?,0O0.>;_IYB%EKA=^YQEFISEI<7476XMRMP5\!0ZW11/ M]@%._EV98T^BSTX/0`-)T\.-W;'4<4*'6.T"N@043^'N1$J7'B$Y6J%QD$+] M"D/Q`871K[D%G*ET+0UY>!M78W^B`"O(R4=5N%, MCO,$TH\/B+HTP!-AKUO_U,&ZB3@^'G&>(IB`Q0N'JF6(-Z565,]!6LK@"]Y4 MS);U>6JZ6)2^O("FF2M6(Z2MX]!'-V8!#9_=(8RX-?4Z'3_?_C9? M/SV`%/<.Y-9J666K+8$L<-#WJ-9'^`,;AE3G\,>W;Q8C\IE M?%O9:HAV6XMG&SS*6L1]9X#]8_'L(=;CX9[P`;CLK0@$)'J.2\[.O1:I^Z34 MC_S"I0R%J($5;[6__T[[*=Z.M^V'H_8YG$/:S=UA%+(5G*P/.:E+3^K&K*\I M.ZG+'1$_!7`LM*?!OPWM<5QV3T`G-PCGOC_@QL1"?`^3SWU[X)C,\=74L#"? M?=OER.#AEP4O'G2YTC'_`]L0E]*W/]P3P_'_IGT3<;K/=#%E#M/>ETU<\+8_ M@ZY`^N><(A@^O4N7WM/4'S2GE^^OKZ_)WEU[?'4GSFS[0!X:B>66!2_;6;/= MUY=9.=E9^55\A8]JF1/[,HU=<,HN&!#/C5LK!IAF,T2:>@GBNA208(K-IH#D M7A7S+]:%YZPLLVVU)U7A%HSA[9].CZ\PW!4[D_5]R<[)EW*^S/8Y4,0^F8O4 MOPX$IYS6P1D?V[VW@L>:8Z`D^,'AA(K:CG%VG"P*\96.?Z-3V/N=^T[=]/+6 MGMBN<1\3`2PVS@W7BDIY84G(C*X1*%JO@A@J&132L#G!@TTUD$G&;H`I:G5. M4W\'W"+KXUC.@=&A6Z+QA_Y%)?H'YH@<_`GCN0FD`!\=JB";?U:\YJ1>:P.H"?__Y+G:O8!AD%,C)T?@[F.G#PPHO>[,U M66T?BW+CKGZS^^*I\B.Z[+#:U^0W"E2==0$8N\\K`MVJI6^U)=.J`J%K7Y9- MR3(O\ZJ(_84=Y(\$SD3<4;=/33Z,!#J#(%8,,UDGU,][@6RK$D&[9N'<4_^( M]:U1@1Y@+"6+B;-MEQ/\L-G59A'[/QC^)\``KZCWU`T*96YDM M*'$/+DDL206RW8,-%%LP(#`@-C$R(#W-;-W9QMY8V^U,W`M:IB5V)5*EZ#C.:[0/W',` MD"(ED?8DV2:S$0@".`?G._]<2I:S'WZZI62YFR4D3E@*?XBBC.B4QJDF=3Y[ MA#?+&24%F?V;4)+`7TJ$CH4B6B6Q(8N-G=S,HE@I8O]9NS%EL3#P('0:<]%[ M-+%BA-)8X]*D&SW^>?9+CXAD*DX,T9K%4NW)Q)H1_&]M1Q&>B@\14F%F,&'I M1'M"T8#2Q7SVPWP.C)#YXXPFL71T<2"IB3759S"6QE+9J%K1XJ(542K M(W`J$TC14AE.6#K1GE`TH`0Z`A)+32L[&,&]X+U.0,8&I8?HRPY]ZM"_"^A= M2-YGFWQ'*H"#!8\A2#L@'_*M>ZZ;HEPBA#*XR>M=5>YB\KHB%T5UL\KJC7]UD]5-"8R1 MJZNK,_+SSY>6N5,(2]!N-@$Q$S%W]M>.3H.(JD+-$,2DA9!)]`4]"'L3#L(] MF6A`YQ2$8+X)<*[`Q+R0&._DBNAE=V&HT7*[RQ>]DOLK)^79;5]NZR)J<7%2?R=4C.7?R M_UN^N<]K-[[&V9_J,))!];1U+(%O5.`6HP$]IXA..^Z">[C$B%6R%!WAN.MF M'#VVQ&`8NHP-8!`:(2;^1LIQS[#G%"#P MQYV\&+A?4/?>F1;W+O0PC",I!`4J0!DWQ)8PX#/)RMRJV MI*K)S3I;Y&Z20-"\QN4\J,,D6&9E\25KBJJI%O.IUONGC763]R$"'J(6U)!R02YT_1A"(N?=`"@=U8<.,^VY_5L(?_D. M=DB_`]=280[V.*<>7.1E_E@LBFR]?K',0_:9JL,@P=K@RZ4CR$48:4@(7IS^>A6,J33RD%G=WAPS#SSL7;98D8Y7F#_QAP'=\;-J8DW M,R@,JO>`P:.D[;9:Y^3OE",**IUUAGWA/^QJ*;S,H2F/SA]N32-4(7F8*KU=Y^U[6 M-.#O""IG3,=@?:U!G;8BGT`)VYCZ]D180#)C_G^)L-`2`Z[W1Z9K/OABZ-PU M@)9U[@987)YOJB?[4#9DF+G8`O/9*3\LD'2O_+3-L=NV1@G07+P0FW9`-A$* MU]42KIL!C\0E":&8++V$XB,YPNE46D"II+M*W672&EMF.D"KLX.>Z4WGT^EX M/LWDM#J`C_&ZWHY&U$'8SN-7E<6=,?%I8_*:@%Y6O%(2K4)L&MK*9Q%2@/MW M[#/,5VTU=+X$57'C)2S-W+`)XMASL=8H:8,H?IR>\N M7/`^/Z.L@/OGG"(87CC.O0/!?A__=`O?=>^=4&3,)!7[C#9MC_$I5Z_'#W;^ MG_-W%S?P_%^(IJL,_(6]]0XSZ#9'H%KT'P['U$*\G>[%`#61T"UIX6:W%;K$#W M!<9KAA#EA"5G<+H)4I;8-Q8\$7@^W$-EWSRBY&E`/$^6G3.2?[8O%_FV(0W$ MZ0X,PU!O*6JO@+'[F/L*$@R_SW`H2=AA3&BFD'"D$HV[!WJ?4.6%?+G*-MM= M<0;)9KG"'#1OSJS&6:_PEZ?ZN6B^G)%-5F9+;P-00TJN]C;@RPZJ:6<#`)-3 M?903#:[P@!=RGY.'/-^T(;*IO!5`M8F?(0Z,*D$UMP=:F?L]JYS4Q7+5=$<\ M%'6^0!'GQ-F+]RG@Y:4Z:#<:YK-Z?T$1//1J(VM%E36=VKW=/4%NOD,\8ZB" M#(5,Z_SAH<#N=K9V2XJR53`FY'&V;WQ;];$"3V*[XME]]=20<^L7_!$[3\W+ M%\A(Q0^<`ISD/57C5L.)S8H4,%9!B84#)!3G30/5Q`9R$7+NQ0`.'7N[HY^V M/@:KO,XQ=Z&N_F!!W#5!H7CG!+28Z[U;;E/_?,(K,XVFCYP/_/+;/GS;J41@ M(M8O-DCW$N=[IX+R0_A,R7+F:$-J`FY'*!L*K0NR_^?%_P08`&*^+.X-"F5N M9'-T7!E+T]B:E-T;3X^3'#W><+P*.758 MS.`W\8HYX_26LD_9;;:@?NX'T"W]?TW_AKL#O=SVH*5B`"[1/!1]NT-#A3SB M!C?7&4I.A]JSWD]/?"0&$-(3'R'XJ"WCD*-3:)Z$L6EUXS"%ISK4@J"K6\<^ M$BM$.^'TT_41`C8+'4U+:#%NP+GB<1V-B@ M]1!]?4"?6_3O/7[OLX_9)B]9`7`(;^Z#M3WV*=_9_KY:;1<(H?9N\WU9;,N0 M]6-%\N)4AK(/K&/UC*3IAMOI(:DTP]](T5M_S?;9DETMLTT-V<2]@U`!8F`1 MC%7(`A#^O[!MGQ&X3'#[!S$MK79NV5[C<04AU;R&)@,Y];M?O'+E!["R9TW1 MYT\:8DF,.)10H;317K?Z709WRTW79:+:883&S--RF-:`=9A&3-"1T^IB# M4TP-LTOK??_(-P_YWK9O M_>7['/I4VP[&;KQ][Z M!?Z,AJ[DN'Q/[%+PN4D*=!`8=T:]&GWU*[6F`,%8T$&>!T]O39??(US'4!K; MLOV#[&/T-22M6(UE?XW37'Y7(\$*;C2$?ETRVLF=FZ/D[J0$'3'#/L`AQH3S M@4BZT.(NMU_Y`51_;P5.D'K5ZG<_D-#(M^5RM6/%GMVNLUEN!QE4YQN<+KV] M'WF+;+OZ/:M6Q7;47Z)DP%_Z<[U.(43KS!+%=2(P5MO/VU65/[*["B*_1*T2 MYZR!2S8(-Y*6GKA6@W&M#!ERA/M%26WT0_,(6P$D2Z#Z`IVO'UP>&?1&6)0G M'#VA,Q)A;@E:HH*N+`MPCXDUXMPPNW[KXEK@O1KX9V/>8V?X^`39TX*-"+.; M.23/0P$#]^/)<>IL+'RWS/9`$"BMNSG=N5:<]R[?YO/5;)6MUR\T&XAN>I*2 M:]5J#G+SO`7@W[WX=76!Z?I$@G)OQ2[!O<]F2^8\A!]-%KQ5JI')["L?L@&$ M`G*;+?).4WL7TU"`3[2CA&;. M5$]"`J.2=C)PMH**-.LH:`E7ZZAR5ZQS]G-!A/2V>`8R8/\A2G#:'A@^8PHU M@RCH87<.M5BCGD-FZ4#6Q4N8@SVH^1IB.CI&K$YZ\1ALK^O78'8$V-D:.LC: M&IY"AIGC\0BT-\!+7D!3>DISVY"@ZKTW1Y,,02;-F$G>.-"`PYE>U)(QU,Y2 M\>V"K:WD<3FF6/MI5>Z*!L-,L[;US9_6HRI-!X`RXR!]:IV M;Q5A'?V2&J>D$V"G2/U1D.0%!M58/#EFI>BR[/LYLP*.8_Y_G%DE&DNURU?F M<"'B:,6EO91:['/;P'/HY:9XHLZV8EV*0V?19\L%8(+F:7/3=DQS+,EAQ%N` MDP#;H9LV96]8D/Q8DM'0H'YV$YX,6C0*X?>UA&H6<<9Q& MSZ#>Z3#U%GK<02#]N$BH6P,.HNA^]`^=J0^A)L=#S?D&)F#URGEJZ>/5)C'I M&?!)[7W%2XKILCY*72[`>6Q[`5,SVZQ\V+-G?0G>37;.`B<_V_,6L M31TYQ[_O?YNMGQZ!?SL%*?J(XT#!T/$YCN/F'XP1'`H$ MWA=&@XA+`Z??^"U2@E##B/\9.0&"]X`[3P\Y01_(_RR'N`0`*S@XL:LU!`ND MAK)T(.8[.![EVXJ&(Z% MUJ5-_0R0@2,LUV'\^I6I$'ASV5IN_-:&(]LP[?D/WR5>=F7[H[(E+GF\\\"` M&0'&)FUU/9C;1>M+S$YVLT?'+QYX$IT2_S)4_Z3NGHQ.;A;._28@C0F5^AYG M/_>+@'5VB9^;XL$O`M.778Y./OP!X-4#L(R34/X/)4IJ[>8C`*21=_W1W2(? M5Z`NE,)"V?O=2"K95F-0`R@,4G+$P-G$<6&M7(V\PC,_9/+-KERQTG7P0N0; M'FNHNV#9]I$](@NC?HG?P_#"`2B>1ZQL9A]LJWVQ9K;]#>L_]Y"LH3$%7G]& MS;CN`?(_$_1[X8,$R5U'"&ZO-4H[R][84!DI:``_[,#C*]O; M;`JH'I7MS%!;#H4,-F$7><[V^VQ+[8HN34H&L7L:WOT M@3HY;@#X6;MS8&D%W2\]O+#+=[?T4?/:RKB^OF"552.'W$0-?2',JQKR1CRI M2<-;LL[TA]:7+(-TBTAZ!5HS^AR*;F*-6]F!JF"[)V!IEGM(.>AA:2_> MBGEM#_(3((`1'3?(]D8XDS,KYL$Q5/KJVC(`+6BM<'U]_?'H?NR]N*TY04?7BFG-TMW6&F=Y3W8*V>7CXPJOPK,U6VWGQ7YC M+\:SA^*I\ILK5*AT0J2ZV56$AY`SL4D9V$TFHG/G6O/P^4@B%'@EK=`K.ZGPO&_E-!0I9$4M^@]' MQ?HACK=6A5()A2IEBXF5#7:!/*IB*CJ49>E_UOBO``,`:Y@RC0T*96YD,K%4 M,%"PL=%WK2AQ#RY)+$D%LMV##17,38#B079V^F[Y>25`L9`0(P5S,ZA80%%^ M%LP(#`@-C$R(#7!E+U!A9V4^/@UE;F1O8FH-,3<@,"!O M8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:"`R-#4V/CYS=')E86T- M"FC>O%K?<]NX$7[77X&7SI`W)H[X18"/3LZ3<3M-?+'2ZTS?$TF$@B!V.5^WRX^@!%L,?GQP[5@B_TD93R5.?QAF9#, MYH+GENV*R3W\LI@(MF*3_S#!4O@KF+9<9\QF*7=L_D"=#Y.$9QFCC[5O"\FU M@PMM M)A&+I_^&N35W5BL8/_UIPM-49#@B@58J<=C7Z/V76'$775]>L8_4*N-$-RGLF MZ"[M?V57LP5=%W$"E_OX7]._XM.!7^'QH*4S`,X:P67?TV&@N$B%PX?K=-G3 MKO:HB^D)1S(`(3_A",%';95Q@:0PPO+,M2XSGL.OAAM)T-6M8XYD&M&V@KZZ M'"$B$D=@5JG1(EGI=I"=Y&`HZ5@"CD#$'1 MOXG$3X.O+#`EF*S+`LRC.A-PNV(&B0XI1(D M%%0$*`6_L$U?0(21W+F#R9:'56#%S_WW02;HWOL&V60@D^0(G:3FRN=ZW>HG M##Z@<%W"I#5=I,&ZTZ)+J\/3Y6`FZ=CIHPN4"@A\ED$ZUX`H?%(DR>PFCBTF M,P&@N+3.^K3*%:85H9;CZ.B?OO`H**4Y%M-F#`YQ.*2%\$TD@7[OE\7\5S9= M%NQ\N]V5V]UJ5A7L7?D;N[QGYYY[?R\>;HN=;W_"W@^[.#%1^;CU+D$)SJ#Z M)AU[GN\>JIOH%AYB`"Z98[T=7B&DPH6!X`JM`;@`=S&$5B>SNVE]F#_I&.C! MR7F8-("0!9R4JC/':A_7ZXOW[,O>EU?V:1-GT?H9/D835PF3K!U>D#MD(DPHKD`F=GA1K2](RE71M>8![0FP0 MYX.NZX\NS@7L-;`&'L)[3(:/CU`]/=B(,/MT#\43BH./,=!/V./2>8CP]7*V M`WE`93V,Z8[UYJ)WQ::X7\U7L_7ZF4:#S,U/2G+M6JU`/CUM`/AWSW&]NL!P MO$>J8715#-8!40&6S0=7I:G:!TL]4[ZJ! MY=2$9+6#FCSK."AD M392P4;DNUP7[1TER]*I\`C'@_Y`D.&T/=+\X)$D3ULC,8[@R@PX.Q:.#51,NP.5S)F#V!G"I M,VAFD3;"-Y1TWL1-M,#H#*&GW%ATWCC90,>Y7@#M&("OK:O6M:"?=&X`XFF="M`]L_K0TTWDV`)(;`^E%[]XJR3K^V1H?VTFQ M4X3^*#CJ##,*DFDPCX*JTG1,]OUZ68.^8!PD4+^RR-2`LNA7W(`FM[4D5,W!GPW\`;A!%JD(JZ@%>12`I[X:_5>H M[WQ8?4LSSA.H/B$AZM8`3S0=D/ZA;763<6H\XP)%L/[J%[94RQC/-DE,ST%2 MFNA7/*>8+NO=U/D"..3;"Q@Z\\TJAF>./*6`39<;SZ'/?LX2!C[Y+1CS,0WZ M'#\O?INO'^]`@@<'"K*ZJV:K#8,J<-#UJ-)'^`/KAPY\PO@E&TJP/>&"8 M#B*N'&R`L[>H#%(/(_YGE`;(X09WD3>EP33Z?UY`>@*`%>R=V/LU9`E4B/T^ M@%AL88=4;"KJAFRG7MS3P!T>\7`SP/ZY?`H0V_%T3]4KX8+"A;708+/VE]CMFI;G[W^#4")M%&\2]#RZ`RW'":U\**.>XUM]#]M>^ M$O!D5_B^:5BZ3Y^W!9)\^`W`BWM@E5FN_H>52AD3QB,`Y%%T^3$<)!^O0%TH MI8>R]\61TJKMQJ`'L#`H)1"#MA3DS4KIWSU4;!\.0A)\K_7-[T1GFSMVUTBP M6@_D)G4'/1!VLC8+\Q5L7D*M@+U:M"O7K/P&HJU:%DR>*2'/)#`0+?FY8,D7 MLIGJV#-\:P/EJ'QX*&$IJ,KYK^30TVRWFVVJ/:M*OXR#0L[2[.0LQM:.A2WV M%L4.R)+Y>EM7%Z>L1UG MT7-XM&"HYVRRI=P/7+F@,/&PJ3F_NUOA,?9L[:]7F_MR]^!/MF>WY6/E:Q@L M4=JE(_K=!Y^M]FQ?5'XJ8KQ!=L6>R* MJN3-0U$M@X`JVR^J%R-53>(1LT;?.G7M=6^^J2O5*'%:9F'[5_^(_:U98=V# M52=GBXFWC;&"?7-&*PB53/JO%_\58``CARM,#0IE;F1S=')E86T-96YD;V)J M#3$X(#`@;V)J#3P\+T9I;'1EM*'$/ M+DDL206RW8,-%%LP(#`@-C$R(#@1$HD MK5Y\328B"(+8Q3[[\@",8+/1CQ]N!)MM1RGCJX,EL M)-B"C?[#!$OAKV#:DC=3Z.$IYEC'Z6OBTDUPYNM,VYTHU;QS/) MA.`6AZ:[UL,/HW\VA!B9\=0Q:R4WV5X,MY+AOR6U$IP5;Q*4(EVK@^0D>T%) M2]*[\>C'\1@48>.'D4BY\7*Q883C%M:GN-!L_`BOCJ?X\SR*6#S^-\RMN;-: MP?CQ3R.>IB+#$0FT4HG#?HO>?XX5=]'-Y37[2*TR3@17$8\-SR/F7*RYB8R_ MI)8N(J6+C1-I,^.XCJZAR64T@9=T-/,S%'3#'(.KC=S5'78R/?"0#$/(C M'R'XJ*TR+M`IC+`\@CF4:TK:!+VT?($0G&0O*&E)`A\!B^6NMAVT8%WPW*9@8X?60_3-#GWAT;^-Q&W,/DX>BRTK M`0X9/<1@[8A]*M;^?E,M5C.$T$37Q69;KK:<=6-%\K)<<=4%UJ%Z3M%P)_QP M3BI-\9IJ>NOB_GFRN6=_?=H\+ZIOO;@9\%DY`)S47/FHJEO=T*`#"->&)JV! MD08CO`%,H\,#LQ>3M.1T`0-!F8+F&01.6+I4.VLA)I/;.+88.V1HQ:5UUGMQ MKM"+"<$<7XE^]7&N('/EF+MV8W"(JRV:U3-+0/O]O)A^8>-YP<[7ZTVYWBPF M5<'>E;^SRP=V[J'^1_%X5VQ\^PI[/VSBQ$3ET]JK!!DO@V27M.1Y]_*8WT9W ML(@>S&2.Z:T_(4N%>9@P"ZT>S`!\T0=9*Y#:4;2?/VD)Z`#+>:PT@)`%L)2J MH\AJ;]>;B_?L\]9G,W:UBK-H^0(_@W&B!$[?$2AHL%$8I$$'B07)45F"@@>5 M[A>VZH_WO:8`09BNX@DP8I24M,OP\(B#$9?"!5(;1$2*3OXP1*;;0`)\BC M:O$M3A0TBM5VOEBS"L24@V"#E>LBH?%=#%9+E]H-+#*_"@EUZK5!?_J>07`OWN)Z^H" MP\V1!!W>RD*"NYA,YRQXB#@8+$6C=B%MV%0Q9`,(!202*R1YKO8N(-:9ZJP: MF$Y-*%.>9[!?%M6<*,A07&A'?*PGC^[="D9W>!7X)'D5^JFT&.7@0M)A%CN^ MSWA=,WRK+UV@"^?H(I:[NF:$:GT;&2C`1]I10G,GJJ<@@5%).^HX64%-FK44 MA.@)CA+V!3?ELF`_E\3^KLMG(`/^#U&"XW9/]PE#J)FDB4>Y"[7,H)Y]9FE! MUL9+NIT]J/D:8B8]1*Q.>MD0;*_KM\?L`+"3-0R0-34\9O.4.NX#:CYT`G1O M@)HZ@V86:2-\0TGG1=Q&<[1.'WK*#5GGC6,.Z)SK!-`.`7B2BF\7=TTE#RLS MA=U/B^VZW"ZJQ=>B&7MO&'J#\29$\[CD3PLWG6<]8+DAL%[5[JV"K:6?K7&R MK5`[1NJ/@J3.,+(@J'KC*9`L38=4WT^?-=`=]_^CS]H:K-HA=;E=Z@H,X]P? M!LTVA6_@EO3\L7RBFU7%VFR'MJ7/GA;``"/R_0G7(>/Q?(<1A0%Z`L2'3KBT M/]E`'N3YQIX1=1.-3/40C6X"#FAR6S-$M3MVL\%_`&Y@22K";&J!+07@J:]& M_P0RGO>3<6F&_02R4`B(NM7C)YJ.)__0+GL7<6HXXH*+8![6K^RPYC&>+!*W MG@+#--$7/+88S^O-U?D,?,BW9S!TXIM5#&N.O$N!-UVNO`]]\G.6,/#9[\B8 MMVF@Z_A[\?MT^70/C#PH4)#43359K!AD@3W-1](^X#]0-TQVBO^$\3MC)+LZ M@<=U:2_BRL%^.'N+S"!U/^)_1FJ`&-[A+O)=:C"[[<"T@/`$`"O82K'W2X@2 MR!#;;0"Q6,.&J5A5U`W13KVXQ8$W/.+A98#]4_D<(+;#X9ZJ$^&"V,1%J%R$ M%QK'./4S0`8VM0)HTZLG*4)*/-!L3#=\CB.0=+CF^+OO$J_:LN-!V0JG/%QY MXL",`.,^;;4]6/A)ZV/-5G;SF\G?(O`DVC?^I:\,*M/>*QV=-9QZ)*^B#OG5WAUYY^"C]^61?HY/WG[Z]NB55FN?H?*I4R)HQ'`$BCZ/)C.%<^ MK$!M**6'LO.SC=*JJ4:O!E`8E!*(07LG:D78B>Z^`%!2WOKCD:]^9SI9W0=3 M")[FD$32@[-O*\*APGV#J?F9IN6JVI1+5GY%VD9=U;Q@\DP)>2;!$[=S/W7& M;:KW#*,^';$V)"A2J(3$5#X^EE`4JG+ZQ6N&HW4!TC*=#[9%N`[=.?.\I0:%I7#AC\K2O!+6TD=#UBE1!24H:[P M_*8B=@'*-7OOZ*;`[W=`M)HW.[I5TIG1W0L[?W=-7P4OO8S+RS-6>34*R"[4 M,&>T+1S64.S%DYK4O2+KC']H?`IR^%V$V#:9E+XGHEV#27U'5;+U4S"3L;@W M%1&2!GH8O&4'#LD`-I*EM&\@VSL93!Z0NPM4DSY;-@Q`$WHK7%Y>_OW#68VQ M1K\)V(:I.\$5S@2/,1DM^2QWLHG%H;8-5ZJ73*L-GN$7(X&6*K'GO[J6%7:4 M9!B);B-`8&@,"[S;D^TXBU["TH*@CH/+!H_?^\H%F8F'+<[Y_?T"S[@G2W^_ M6#V4FT=_[#VY*Y\J'\90L+1+!]B\-SY;;-FVJ/Q4Y/$&G0N2Y9P!+3NO*O+3 M"3HR\,3Y([(#^IY]SN;%IJA*OEL4938PJ++=%'L^D.,DGC]KU*V5Y4[["DU= MJ4;"TQ`+F\'Z(?8W9H4J"#4H9[.1EXVV@EUT1O6$$BC]-XC_"C``E%835`T* M96YD,C54,%"PL=%WK2AQ#RY)+$D%LMV##17,38#B079V^F[Y>25`L9`0(P5S M,ZA80%%^%LP(#`@ M-C$R(#7!E+U!A9V4^/@UE;F1O8FH- M,C,@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:"`Q.#8S/CYS M=')E86T-"FC>I%A+<]LX$K[K5^"T!4Z9"``"!)A;K"B.-C.)9JW4'I(YT!(M MB'(J*=_(S=O8';S<`/B3+LFO&+HD`"'1__4`_),AJ].KJ6I#5;L0)XS*# M/Y(*24PF6&9(78QNX<+N>C5_,Y`"'SVY'@3'N^.-#",@/R)4PH,M_`T?D" MOQY&E$3S?P%MQ:Q1">R?OQTQSD6*.V(8<8G;OM#QYRAAEEY/9^2C&VVC6+"$ MLDBSC!)K(\4TU?[!C7L([AXFBJ5)M66*SF#(),WAD*(K3Z%P$Y(1>!JZO27" MG5+^+9GE*S1*LQ%30V;0"R8H)NHACD$,Q![TV4P%ZMODZ==)@6742=] MYMC@`FX0[$^RL!]%T-T="<*()$(=<$ZNB_Q^6S?DZ14F>&);HV<=$^V9_*-`&BE]P*L$MG63[9*,R^9W-[X@XS-Q6`ZD"(5'7AD>M6C,R3(-/I](+\S&:,?*5_O+F<3:=()J'3"(S;78>X M)>2,G"4MN2[:*G,&TB]YE:^*3>$A`06K;0\I"%,U`!ET-=.>P299( M.3!@UH)SMXH.)>IU-T$[3AT43)(MD5/&ZRQ`W^5U?D?&=_GF?E7`C$N'CN/BLM6:I>?)^5XE#.A"A\'%$^5<6!/XR+JBGJ"XRV+K8T M$22T@D"HIH9#@4(/`F]GUL?1_3J'^%3GD'YVB^U%\.4WQ(5:2940P@T>*;U/ MX+*%VM94B,C2IOQ15+N[\O[5;)TO7#C\5*_RJOR1-W['MCJGO23C+'F)\J0T M6%(F4$@F;3A,G#=^H6^+"!/Q.G>/!_^HBQ/*>69O<'+GJ_2J@"M8_3[T?N5> MC/-U>;NMJS)OD9Z0*X':M?>*)RNWI\3D!DK?$/2/+NGG"E+ODEPW>5/LAG2] MB"?>`_H3JR=Q2R.83<]4HB\`+Q74&Q)=;^.<4+091X:,,XX@AT/B]U4@WC9, MTN#:6U^(5?X!8+<+?&OHOT-`39@TUAP59M)T4+]0:[6KR2TWP@T@6CSM?A+& M*?=0!X9ZNG@6'.#`(QMDY;[AT"X%TH_;AN3W]VLH3F_6!0L40]F1LB[1G/#Y MQQ"%@6_K(9YO`+C"BFL0`2AI7[(L4QU'?V0R'WT;^4H2`A-P@Q0A76<(=QV: MS7^2"MNRD]U#:E6XA5A8>V*_GMJM.3:G@^WY7V"M(2K+`][1.=Z>00J%9C!P MC_7;*`!+,?ID4$PXYO8<\W!@0.[FK.0:OP_9.[@QLTDJ2&Q8HK$0>-M5R`M$ MF'="!16I%%H$B`BABW_>.`I:Y:QO#(86:N4.-#O!Y;."]T2["T=O7J!_J.*9 M/;I=`]FX0N)0)F4O\+P,?WOH"#[G>1`JY&#WXB]PAA*-H-6'-%,*^S%!-0_4`M\+Y=[-\O7B`QB3@;EQKOQ$ZBZ@H!.9FV" MF;QW/+/@W@<\CTK6+V"[)2@QAO!K(;K/7>-=-FM7/XS7N2_>KHO%OBZ=SC1% MC9WLRH\+RZ^T\*13"R*,(<<(^MG]]+/?W!3U:W+<3W+L\W3V\DXR\9TDV)^E MD-)6WJ-$DGJO=YE!L,3ZG^S^+\``545I/0T*96YD,9RWRZ>Y-PR`_9)QE6RO(='EVO\^3)+ MD_GR?U"W8M8H"?2V;2#U?7R4_N;#]?<*92 M-L^931-KYPI*N3]DQAUXY@YFOA"&YSG3Z34\JM+5K;N^2;B_V]>40$U0[4VX MJL+5Z_+N^0)^G^?_7?X=KSBLUG?WFX=#\K:%%^I7!;<-P`W7]J/.(>9$C1H\*PPKI.(GN%;F$.V5 M:V6PA8=H+'U<>!\G$#7?;?\,EY+KS=/:GZ)!^Z?DGQLP'(.'0Z_@S:OD/5Q@ M,MU!;!7IZOFY;74!0\7D_58OA&(Y+SC8Q3(-@SD,&E,-&NEA?MALDJO#YAY# M.T]54C823,^9-%QCW!5&F%`+=M>Z[,#2ULK*'_=/F^1PMWH`>UVE?VZ;)_SC\_ZA99T`WR(M]EKW[7+V^\QUI+"%"RKX`1:" M0`3^_#5Y0*9I]YJ_'UA6:V0,Z/J?0EV_]-V>*R2[YOVA<]>SAOOVAV3U^+C; M.F)P/!YY(/?WQZWG[>KI[^2GZ]VZ[OG+>3^0(/;]>_N^(?/<[AS]1`>@7!WQ_?0ZVC1`0.=IT_[G;_N M`Z+-2C!`K\JDD"E>1)-@FE1_ M;%'V,(?Y^:B:'!91IR.ANW`\;#":BO0>>PCF4.7,0&=7FJ'0Z&,M"J8ZPL1I M!B],+-ZUFP$M98T23+4)-TC%3I6$LY8JX(Y,0K;7Q@%;ED^P5W-<:D3VVD:O_N/[3K\B1MLU-"O'IBJ@@X_9J7,W MP&EF^AK;1;J1"@9EH6,C9>C4;WWP+OR+ MPOFP]63_-P@_-:%`5?W@?*$ M7V%"6@S3_KL-3OJU?A5RL[(FYT$?=\<\*+BGV&:G MP(SZ..9%P77LQ9;\Z\PP)%?6\TME4I&J>"%B2(NT^&"A,9L30T744KCP,DWRJ/4790EP]-@VC@^ M:WXGPP0!W_%J2%\(+M[,0;^FHNAQ9Z!H$LZ*H*,B':4"9=<,R44#I4%N5N7A MC5_C%)DOBD'*S@L)"G\LQT>E;)=7&PY_T6)L<9RQAP@Y+U`;A0FJ")S\Z;?Y M,,U1L#593ES$N[III)>*"8TV$6< MR2Z@B@1.1F2%D)9>0 MH-DX",Z@$J,P&1ZYT/%SFC'U55OZ@8*OI0YQ)'P4.OX;30(Q^Y;PVS`_& MC:!1?B"MI_-"X(KA7$E'U;">((QALF)(G_?]"!RQ!N&T@!OZS`U408,YIHBH M2`-75%"K)06>:"'(W M0Z2+;-&[A,S(\`9%$'V1:[K>/$$$T7`.B2#Z*A5%4.S#2T50KB/U=C[)P8@4 MK\1Q6N%(JY=2ZX$DFJ+Y3`5C+'LMJE(: MGJ_?:AXE*Q*V"=E*N;QGLPNJM\U>@WVS?7[DKIW@+4`0B$V_'1>(;7`OF_./P)VE$&EX+T_^!XE(=&:@ M6!*XBS/^7B-&P^.X1LP,^G]TWZY[19Q59P,DB@<]%,T"1GR#0\NBI]"JA474 MQ""%9@6SEDR@%%P577;+5&B!;2IL?9#*@4^!5([S3I$**&R)J1$U-E_U#?@V MJ"A&:Q3&]A5[074'*:D-&W5%73S6AA]JE";"T&J7CC3@!XS";9UJBE45,)_1 MK[.J4H7;%4(=,B1DTZVI:G1C@X8$:IITBA"`B3-3.LQK_>_>#PV=-K2778A4 MT-)OKP<7'S1($V1,++X#;$#Z86@.)"&Z>)GA-E(1PST,:,-QB%T^H)4%][W2 M6RME9/A*('YKM3K^UHH&<\+174%E[GL8OZ"H]O,\N.]AW,<'C>T\Y:;]P7?< M-"LFRU5$1GA]&MYR@S;-0\)"'DE8=#"_;-:UQDQ$&;B#"'."Q(5$RR*8`$VD M;^8<`*J<^Y(4@[D+&M2)2`6HSE(Y)1>XCKP\-:%,QM2+[&U4N5L.6^+&1@41 M+-5I&QO;SWR*-S;2$>!733C+5/4=W=7H\N2-^P>U#LG!TZ57:D@E&:;A`Z15 M*V^!WK%NRCSJ'1AZO.OMVU$/P=C338\NHOU'VG-;M.4H']MR1'+C%*D,'@=" M=\]1,;[GJ`WTI=(:?L]1#7046DF\)&P3I##U]*^Q1P82]7+SC*7J[>!P<7Z;2^G2RE'7?ML91V!]Q+<7]8IE?@:.\+ MB?"FRF!3?1?8GP1N(OI7`M_8$.F?NTB88/4.@RI3K[1ZAVJ$'OZ6T?,D"="$ MZW2HHK!#.QL:^[#:;`0]H)L[L$:YTKAO'^JVR%QIE9/T$4@*5YZ"+NP/ZT5' MV1_6^^`P69(Z>+H41M-U]2LV>O:B#?>%LQ<5W!.S%S28DV4OFC!/S5Z0H$Z4 MO:@HAT"JLK!LBN]\7-/Z=3[T41`VF3W&J21`TWW=HV"DVTMVB[F>.'&W6-WH MB;O%>A\!-\'V1UWI$WP5: M(H&[^`,C3TO5J*70DLWZ/AD_7>O)PJ`<>!6M)ZV!,3E.2S0\TTD]:06JL$!+ MNJ0EV]KD-4I,V!>VL:W*'M]653=[VK:JWN<&>8GFS,ED5>3+,V15!^[+RJH: M[FFRB@AS*ED5P3Q15M&@3B.KJM'=IJ^OETM8;R3+F]E"2J8S##XP2>/<\(T; M;2X5A=.%"E_[7ATV?NOK_7PATR1GSD"``CP$_L#G.C?IYDVPI.^]R;#254R+ M(KF=*,C56,%"PL=%WK2AQ M#RY)+$D%LMV##17,38#B079V^F[Y>25`L9`0(P5S,Y`8D&FB8&X!E0XHRD\. M3BV)U@]P<=,/2:THB;6S`P@P`)YI%J(-"F5N9'-TR$".X`^Y9;4V>FF62L3CN3](&F()FM1"HD%4_^OKL` MJ)O=-/:87(++O9P]NX`%V2R>O[T59#,N.&%<5O!#K)#$58)5C@QAL88WFX4@ M+5E\(8)P^!5$.Z8M<98S3YI=7-PM2F8MB9=MDH5DVL.#=A53^NS1,RN)$,RA M*C]*ZY\6'\^<&&D9]\0YR8P]N6%.$OS;1JE$J_A0HA?I+Q:BG_+DJ+SP]'*Y M>+Y<0B!DN5X(SDSRBX(1GCG(3S&AR7('GRX;O#PL*"F6?X-MS;S3"O27KQ>, M;ZXH MI1/&,$L_P*>:UINX'HA(:LD2`4M@=IU7=5[],&L7)5S'XJ_E.\R.RSD]D+2% MPCDCF'PJ.P2*"2X\)G>QY!XOG6L!G/H(9^5GAR`)#K&"2QY+"CX1*8]^4;#1 M]\TJ=%.[;IMZ:ON.U-V*O-K6XWA:@EQ_"[N[,(PH3O>!O!WZPSZ[SI644!HC M32K-=6IOEHLOBYB]]1"8)@I(%JDI-;+]#](A+Z[#SU]`+3!V^CZ;^OB4KM'( MRZ,RDD/-B69N].!JWP]3VQ6:;L@>$H+LVI'49`?YP6(82`^W=2$@[EA!Q;P" MH(Z$LT?"R62T1CX8NHF(:*8HJ4>RBA)000*9UFT75DFK[DBIF(NT;D#)NS/EG_I^L?MA&SD#!;;4(MGB0EH.L\VH![G.?U/ M-#2'H9W:,$*1UV$8@/$027W7?PU1O50`,WD":2-B'2MP$QP-.MO/7XZE@6.0,^Q0_RBIUDU#)@^,:%8^U MPR"^'+`ZT4R=K)!8"1AV$%\'N.!T@7$2L0,,84#6T?1I5AC8V8'XTE1QV_J1 M:6'@-)0VM;/=9O_=T2&9DF??G2$:=\4XSJ&7FG9?=Q/&7R-\EG9P'%`4.FRH MNS&O-7%"WM=?H7BQ]0A2K$=B#03I,*OEN?/T6%!P*GGJ+/#?6WKZ3BIVF0)] M\^>O-R]OEK>7NS)LREH\GE%`*R,J<3[[L+)R!B/O;>_Z%G#XI8W#U./,N9WJ M*>S@P/!T4M+CT53#5=GO'''.SS,EI**,BG.8*U-=G.PH.7YVE<'_`'1YXA'S MIJUS8C=3P#X4=`=5@E,AB]F`&\VX5BZ-M"NEZEQ)^;DGY=&X/1G?82Q7VP4F MP9FNTLFM/`[X!,^+GS-SH0TJ./G'+#2<#.#`KZV/YWJF=?K7X%\!!@`G@M>Z M#0IE;F1S=')E86T-96YD;V)J#3,P(#`@;V)J#3P\+T9I;'1EM*'$/+DDL206RW8,-%O!:C#0IE;F1S M=')E86T-96YD;V)J#3,Q(#`@;V)J#3P\+T-O;G1E;G1S(#,R(#`@4B]#%LP(#`@-C$R(#OV*<.V3%AX@;S%A]QE#H9IU&F M#YX\T#8M*]7A4/1XW%_?78`4*8F2W7@Z<28"""ZPQ[<7R&$\.#S[PF&\'*3` M4I'A'Q@NP&:<91;*8G"+;\8##A,8_``.*?[CH"Q3!JQ)F8/KF5^<#1)F#/B? M:9ASP93#!V4S)E7GT3$C@'-FB31=S6Y_'WSN,-'"L-2!M8)IT[)A5@#]G_I9 M0J?20T),ITX$L3S1VSJ)]D7,%HAEM' MU_3S.(@@'GW'LQ5S5DFD'YT,6)IR310)SE).9)?1\==8,AM]&5[`)S];Q`EG M*F*Q9BX"YV*%3SH,J?4#3_U@XT18KC4ST05N55$^]NL%<#^*Y.$)'_#;R%HB-QHE3`[.UM%5LR'$>(2O3^?+F8HY5Y ME%_Y85K`!"GF/QYH*)_\(N3S&Z@685[=%7!5+"M`7&9/\/<\V#]C%AUOY2VN M9JP#W\7CM+A!T'0T1M`R!#J?^\<;/&LZ*6X/8`C715G%!B&=Q$AR^X2L/$U> M05B_J_>B($@TOUV4L[R:+#Q1$"-!S%*-D>LQRV0C#J_%26609UE4=(J.\(SJ M#B9SY#59PK+**^]SQ:R85X`K03ETHTSSH-UE5)4/Q0%<+V;WTZ(JO''\6=>+ MLBRN*P8`NWW2:)\J>IQR"TU)T6XH$S5PRB8&38WGAWS^$*.%RB?(#B!.2`R1 MX@IFN#TR"$UYHT>&/9Z=^>1CN*RWDEF]>Z%73:LCI#=2\&\8]/'L# MRMM!9RGCYH4)8H=!M+&,KPPB&@%%P(T/90V"A`\(`O5#HV%59:=K3=*AA(9`67FY#) MVB*\KAKO\CB1&,5D!-+_?ADG&,P'<((CDQC[*$=$<;0H][BP5I(*\$_G]F<= M7:<9TTT>)7^[;CS0YU$2>HJBRHCSJ_?PV_&">6T-,UX8&E7FF);8L+3"]`2LZ-=#I^C<>FUSM#L4B)5L M:?:9QQ&Y,X&<;)(UQM$A*C$I3J:3\<-\O(0_SM:EM"R53G0"ONM"]4L/EG3_ M4]`K@_51O2[H%>4G\XN"7J%I.A'/0\37,8TO?9/:B>F]`=UJ\HL#6F$MV(>* MW8[G9T+\!7!ZSA*;_#:#-^HU7>X&),VT!]0&P6T`U^<-G,3<@-3.IW!KF,"V MG\+=!40%]3+.$V04%$3A"-$&]%Y0:1?6Y5:I;5P%LPY)-G#5C>*9IPW*-7KM MC"8IS:OR\(X`DZEHLV\O)CVV)4S\Y/3F,2]OX/U#^3BI_NFAKA$@9MB+R90\ M';BV=`UCF#,;")0V+,/WG$FJDTA`UZW],84[3$?^;?-S1%5L-JA-8Z>]BIL: M[#2_P"LA%[3]58&3*IZMW?/04LW+[9O)=@BMFM1DY4F7T4E."4\=D%V^@M MD8EB0NJ-2G-$2B#V/P:ACS`H(N93[(3H^HX"(+)_P;P/6ZWH?=L"14_U69][ MJ3-FU'I[F-K&D6W0\\V:8[8Y954CO*!8L.Q*4'PPSTK*\>*;B?YN[7Z?T.3B M2CW3U/H\UY,3-U-EK0");U:MJO$?+[J]JL#;"'=M-VK\5Y1GNU&/'D*2>Q3KY&4+S26-4O M:+E/4$IRF/W6)`WWNSJE;/2%=-,6*98L"D')>1/*&\V@C^33V55>7N=(E=E=GP5"Y[8K(N]_RO%]N];Q>K[F]:M^K?7Z_2ZO!+K!JC)N M?93KBX(U#0ZZ=_,-1U,HDPC.CK%.KN;VN9H3='MN!?J/KK:N2>MJ7HFU9JGU M-<(QH\\G)[V9J3\'$(IU0;THYG>+HH*7X+C1I]5-@G6D0K=)("2=:KL$+,F8 MVO8BZ3_1"0Q5E8;:S>H:F*SN.9=U#Q!3":WE;N$*!S@'UCO6LU!I#U678P>L M:@46MC<9C(,S".$HU2CC'9136?#J_BO``&87^%X-"F5N9'-T7!E+T]B:E-T;3X^%LP(#`@-C$R(#U_WZ MK@V`DDA)/FYF>NI,1!`$L2]K[0LHV'STZNI&L/EVE#&>R0)_S`K)7"%XX5A3 MC69X,A\)5K/1%R98AG^":<>U9 MFN=.*ZR?OAOQ+!.&5J0898*6?4K>_C)6W"4WDVOVDQ]MQJG@.N%CP_.$Y?E8 MX\Z$2^;\163^XL:I=,(8;I-KO*J3GK"-'<9&)G(SK3;GCJ<-5<*?>N;/(.X$820-Y MF<<3`LE-!0FE@?&"+_]8U+=URU['?2(L&@`X$]P\5',O+75@2*Y8*GEFP96( MB>Q$R`#)ZWE35:MJW3(X[<.F]DC@[GV]K-=S[Z@>(8I"GQ&=2L6-`M0#B=9+ M%$*;(/'7ZH*UBXH]K.^!B4JJ9EO/UV$89B[8HFJJVR=_PZH__/5S4VVW;//0 ML#*J[)63\+JJ`/^J*U7Z\':>* MRX3-ZB56;8*`5((X.A$;[/91GM(!?:`?<2ZD' M;I&J"PX;=_I0KA_&)BF;)U9&*L.\.N@$ZLO#W1IGH(7RO4]:S=A3$#<5EM/M]43^V]PLBBX0Q+:@9A'P1'$S>/2 M4\,D]1A+9D\0Y=<0^GY^$=^%(EBT MGFV:5=G6&[^HPUKQS""+][&.G`+H*NBSK5K:Q238HUVP>@U9]99MV[(-I/(! MA9E@'%)*842P#HQL'A`!=YO5YV755MXY?J^[3=-4=RUGC)W/3\8XGNEG$M37 M9Z/"EPHC)2]L3$C"$P"X+]N2O:G'-ME<+TJX+6C\8[DNY\'6R61RP3Y^?#M, M&-!967%,.%7@039T=-;ACB=DV)NG[UB4W0D^(=/O>-);&C9I_<)T?L8AVEFJ MZ]$AP_1)&M*?]P=CK[:OV/NR*1=AXNVB7'F/%"$%1`9\WM;L\*V#L5]].1TI MA#A>T$YS]`S*H?)RZPMI;#^N\/\#-OP=+8IEC]"9_<@^_8:9^Y$VP)!>QA[D M8GH]=B%X^X:*_-!8;=2!I4>I'8N<1'X9P*6B-T2L[^]+RGY%0@X@VS\C&R+4 M+M@[7)$5:T2@38CEF^89DI,R_QS#-?J8O`,TLQV@>4QQI/$2>JJ$>$=ZFX3* M@^QS_[I$MDEI>HT"1F:[)#R9A)O)A%VM;K]GW[S=<&^JY=8K0U==Y*B5Z"OW MRIRHY/*T'2;+N#"]EY-G8B!#(Y#O%SWG'VS'5($>2Y_I2-X@8Z$QF#^LYUOV MPU5?3V0FEH[+ MBT-Z;\R_'-)*@E7YUT?URU8=N8!$2XLBX(\@JWV7='`H&0#3#4]`V^%X#&-_ MW(%*XBWD.\KA2*Y2]C"5U&V0?GE(T[0B]Y@2#.=@I;<`Z:%5Q]A*[G*A@X-4 MWF%K.LL+OS98UQEV-JBD-L2YKSX3G8DSB;9HEX9/@G+"N02*'US>/Y;-/?O^ MH7FLVS]/K(X0D#`4%/?2G=%I`9^/G@\I2>[17_MCW:*6/ M$IWHFGTCPLFNK_Y9WXL\/XORWXB23(NB=RB'F[J'@\[L9`A91&\P-]WQZ%/R MKJ04X)*V^FYP/L&^<+L3W4$BZ]*HZ$Z=!TF>\LD*IWLDF9)165U7--5LD?!) M@$@H[?-K/N@M(41SJ(%]?S[U(@[\%%4].\*Q(5)U^%D"Z4MFR(2$K+([ MA@P:#4^0R]5MV=R5]U6SB63Q#!5<&1/[C'17LVBD8A-'C4-HT"SHX_D$SU&; M!O@2-@E7:B?",?OC1[KJ9'A\23M9V`>EU/T_J=:U`F>YMNL%7LHUI>S!T>[H MX]PIL@V(=G#J&Y!-*4TT$#C7(=C_)]MR++`'"OU-MO4MV;/-&]&KPGNZ$90% M2L&9[V"G0XV`C+GZNEHO-CCWOP3*00-`Q7!E+T]B:E-T;3X^ MX)?=0HE*+'X72L3P3PF329.*+(VE$YLC#1X7*YFF@CX.W%9:&@<=D^4R,9.N MDZD62LD,I\9#Z^&OBY\GBUB=RMB)+-/2IN,R,M,"_S]0:X56L;/"5;0[&:!U M5N-"JY.5WJX7/ZW7L!&Q?EBH6%I>%QM6.9G!^1*IC%@?X='U!C^>%Y%8KO\+ MMHUTF4E@_OIO"QG'RN*,%;1BA=-^B6[_O4QD%GWY>"?^1:UFN5+21')II8N$ MA=F+U?P MV2U_7?\#3Q?K<#QHF10MIYJ#95<3A\1RS8J'FN.Z'I]QOP?A(ERO>T5M00'>PP+&J,3L=%_=5; MX"@M6G8"L'7;'(]-+;[TS>8W4=1;\5RT;5'WG>@;LO-NO?A]P5<$GX0MAU37 M!M7C/Z)&GEV^4N-0$$X!^(@>`)L_7WK,:IGHR7.C*U0,>D3;?FHW^Z(K^4*< M<3=YG'$'C\Z'HN[9RVRZJJ^^EF+3U'W;'$3SM6Q%][39D^45F+8:-DNPRQ-_^W$`OM)^)=SL M9%OZ<.GX2:WT`TH-U3!_C2P3<`I*3'>_'0$"13@"1( M5[07]^6A>99"_%@?4FVQ?4$@+KL3$!4/;LGI/$F M?Q!_`=!)\;;LR^HPN@/(-F(5C?\2[9[J72?^^1[.4I<#$X@$H)XW8%I%VLV\ M/P$@_&`FVO%`,[2!S"7O;Y-[;(Q:7)MJ@)_/HMR7Z MEV`UXYUX#""W&9X2X@=(AC]@N+!<)W86GG!!7N^$V``(S8MFT90)`]@)YC0+ ML4Z-[0!F6N<5,#,M&)">'(C29HGGG+*$ISS1.$W94S/\P+T"?P`T([H[)`9# M&(*A<:.>`>M]*,EX$YL2J$-08/[`@ST&%D9'213IK^&%S2#[,5?SPJ;63Q\] MK])\RHMWQ_NBW13;LFT@BL"&\FC*$;ARY#B>G7ER(SY]NB74!V\;';O1VUE8 MQ,M6X`;E!80IO'SL/+/9FCH==M((=DS=F]QI?L)#BR'#0T$VJ3>B@?8Q0X-W M1)YXA;Z(9!W?Y#H^`;$RD*S9LZB8)WH.8G+A*.0LBA,,!W,V2\9;\A(%]GR4 M]4AG16)5OZ#G_JB0T2;N[*@F`-_O\"N%:0=H!;!2$!!>V'$4I3WUTC[(>H!E MYR=Y@`9P\B!`%!FA(9M<@>$7L`H;===#5672A23'7[?6^F*.\[FHBUU)J1F+ MU(#+0,?<)1,ZIL&<1T'5T6EW`.*V.(A'Q#E(`-O"&$T-#ANK2=S@).JXQ&`7 M?KKCAP,W,+%"[V&0)&^%SBQD/IR3HK"C\4!M'-R7!UX`-P)9Z?UW)L?#4[WMI#^P7W5V8%XZ<>EU MJ`S0"*!,56;/0)GXRSM#B.G:3/`.S#+"ZKQ[%@%50V`G%NY#G$[MG M60>6IG"":[..S`CC%.:^ITSN7\TZ3)K[$G:\NSB4%0`2CH>CZL!A*E#FQW+S M5",XTJAH?7%1U7T)QR*DM&55RQ=DQ]@@)%?ICC%`4#H<5=".]JF537B?GSLI M_@Y1WT9ML44Z%*&.8-SS2X@A,\=T' MWV4PX>-Y>`B`Y1=:PBJM7PV!AONIZ7-7XN>1/N$.L=!+X>881&SM1O!\MK7E M'M]K,(GVZ[#68)4EAT,V[(ZN/)X+F0LUD'?L-)^8BR=)9Q;YS&(0S<`/%T/" M/,NAE*L3:WI%Q3*I M5`/2-%,E%H4$,.;T92&'[);,1C^(W&(F101'@'B2Y&=9H\E]%2Q`JK8S?8([ M,$`KPN7MOC@^=D,9'V>C^GNW@"VO_A4'BY?U9,@OK)F+?6P#@<+=%E+04+)_>&J?J_X/ MD`T4C*I%-KH(I>(TVE\,\(%Y+GCDE=R(3ZBERLR(.94&(YYG-Q2!"T'YR)AT M>`9HK*HO*P"X\(("G.4J)`,]=4@`J$6OI[QF21X22XW1^<-(=%]M9-GDO9%? M6J73!`3*`ALJ#:HPA]Y)6I+"P&7"TT^UKS?MI,+`M>GPB1L0[`.;L6?UIHG. M)`"'$ZH?X81>#:9CD*/XO!&H$N=NS'N&LCWQXG#P>G?O0^14(Q!H`5M;KNFZ MS2"&VIR^S)AD-"P-C)MS@:!7R166$Z>9QUB6H.U7=..T$,FH$,F&=TPX,GG+ MA-WA/1-VOL$>-+UHPAXE#8/^Y>:\8(OC)&@IYYLAOW@IM2!%>$$0$H^;LA_4@'1@]%I^ECN"%>^W"[7!J`/!!&`GA%=X MTK\#&$KZ<^+[5&89:B'O9L?A]/\B<%8(A12()&#)5?8*\5IQZ4-%"NT!)8'+ MGVEJ,-E?=Q[[0SEDK)=OX!)3/0!G#.YLZ?35O2 M[L]!Z=._SP1*NVLH/>7T*AB>.=%,R'SQ3SG$9ITBF^,Q(7CY#U*Q4?G)>U!O M&W\<_GS$\Z&6^I\``P`O8BO]#0IE;F1S=')E86T-96YD;V)J#3,Y(#`@;V)J M#3P\+T9I;'1EM*'$/+DDL206RW8,- M%7!E M+T]B:E-T;3X^7!E+UA-3"]4>7!E+TUE=&%D871A/CYS=')E M86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,BXQ+6,P-#$@-3(N,S0R M.3DV+"`R,#`X+S`U+S`W+3(P.C0X.C`P("`@("`@("`B/@H@("`\&%P+S$N,"\B/@H@("`@("`@("`\>&UP.D-R96%T941A=&4^,C`Q,BTP M,2TQ,%0P,3HR-SHQ,2TP.#HP,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@ M(#QX;7`Z0W)E871O&UP.DUE=&%D871A1&%T93XR,#$R+3`Q+3$P5#$S.C,V.C(T+3`X M.C`P/"]X;7`Z365T861A=&%$871E/@H@("`@("`\+W)D9CI$97-C&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O M(CX*("`@("`@("`@/'!D9CI0&UL.FQA;F<] M(G@M9&5F875L="(^9FEL93HO+T,Z7%5S97)S7$]W;F5R7$1E&UL;G,Z>&UP34T](FAT='`Z+R]N&%P+S$N,"]M;2\B/@H@("`@("`@("`\>&UP34TZ1&]C=6UE;G1)1#YU M=6ED.C`X83DY-61C+30X-S(M-#)B,BUA-C0S+60S9F5F.#&UP M34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AM<$U-.DEN#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_ M>'!A8VME="!E;F0](GRZ?+/KI,I$8MQ,:2N2I M'PKIOFO`U_50SZWW<[B;`^3PS\2W M[;*Y^3/9"X?S2**WH_!Q**J/N<242-3*@@6%^BU.@2\9C7$OL232'S%1Y]RN M0WS--0_QVANQI_Q5^(3XP$=USRE_-ROZB!216:S^19@`!I`3"8- M"F5N9'-TF4@-C0O5'EP92]84F5F+U=;,2`R(#%=/CYS M=')E86T-"FC>8F(``B9&>1$&)@:&!B#!8PDD&)?#N-R+4+A3-A7+#);"!9AG5PQ5THBMD/H'`Y[\*Y M('5\1T$LD.6,VD"_N7*`C&*F@&`$$0R,0(+I/XP%)AC_`008`(Y_'*X-"F5N F9'-T